< Back to previous page

Project

Chemotherapy-induced myotoxicity requires healthy skeletal muscles

Cancer survival has increased significantly over the last decades because of improved screening and the development of novel therapies. The downside of this positive evolution is that cancer treatment-related adverse events affecting the quality of life of cancer survivors has become an emerging concern. Physical long-term side effects of anthracycline chemotherapy, such as doxorubicin (DOX) and Cisplatin (CIS), include cardiovascular complications (heart failure), peripheral fatigue and muscle mass loss (wasting). While the cardiovascular toxicity of DOX has been extensively studied, this project aim to investigate the effects of DOX and/or CIS on skeletal muscle structure and (mitochondrial) metabolism. Additionally, we will evaluate the possible beneficial effect of physical exercise as a strategy to protect against DOX and CIS induced myotoxicity. This project aims to lay the foundation of a novel joint research line of the research groups of Movant, Cardiovascular Disease and Physiopharmacology to exploit scientific and operational synergies.
Date:1 Oct 2020 →  Today
Keywords:EXERCISE, CHEMOTHERAPY, TOXICITY, MUSCLE FUNCTION
Disciplines:Molecular and cell biology not elsewhere classified, Cancer prevention, Cancer therapy, Cardiology, Organ physiology